Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 studyShubham Pant, Christophe Le Tourneau, Toshihiko Doi et al.|The Lancet Oncology|2023Cited by 195
Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: The Final Results of CheckMate 651Robert I. Haddad, Athanassios Argiris, Kevin J. Harrington et al.|Journal of Clinical Oncology|2022Cited by 159